Tushar Manudhane
Stock Analyst at Motilal Oswal
(3.13)
# 2,484
Out of 4,423 analysts
6
Total ratings
100%
Success rate
30.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tushar Manudhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: RUBICON Rubicon Research Limited | Reiterated: Buy | ₹955.00 → ₹1,160 | $1,361.80 | -14.82% | 2 | May 30, 2026 | |
| NSE: MANKIND Mankind Pharma Limited | Reiterated: Buy | ₹2,640 | $2,414.20 | +9.35% | 1 | Apr 29, 2026 | |
| NSE: CIPLA Cipla Limited | Maintained: Hold | n/a | $1,351.80 | - | 1 | Jan 26, 2026 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Maintained: Buy | ₹8,050 | $8,489.50 | n/a | 1 | May 31, 2025 | |
| NSE: AUROPHARMA Aurobindo Pharma Limited | Maintained: Buy | ₹1,370 | $1,497.80 | n/a | 1 | May 28, 2025 |
Rubicon Research Limited
May 30, 2026
Reiterated: Buy
Price Target: ₹955.00 → ₹1,160
Current: $1,361.80
Upside: -14.82%
Mankind Pharma Limited
Apr 29, 2026
Reiterated: Buy
Price Target: ₹2,640
Current: $2,414.20
Upside: +9.35%
Cipla Limited
Jan 26, 2026
Maintained: Hold
Price Target: n/a
Current: $1,351.80
Upside: -
Apollo Hospitals Enterprise Limited
May 31, 2025
Maintained: Buy
Price Target: ₹8,050
Current: $8,489.50
Upside: n/a
Aurobindo Pharma Limited
May 28, 2025
Maintained: Buy
Price Target: ₹1,370
Current: $1,497.80
Upside: n/a